Defining the new era of biomedicine
Danaher companies aim to leverage AI to make the greatest possible impact across the entire biomedical field – from the earliest moments of patient care and diagnosis through manufacturing therapeutics and delivering next-generation treatments.
Addressing the right problems
As AI becomes more prolific, it risks becoming a solution in search of a problem. We are building insight and perspective to discern which problems would benefit from AI and determine the right approach and scale.
Ensuring real-world impact
We are driven to ensure that whatever we create – data, tools, AI-enabled instruments – addresses a real issue, whether pressing or long-term, with potential for significant impact.
Insights as strong as the data
AI is only as good as the data it’s built upon. We must make sure the data we collect, prepare and use for AI applications is useful both at the level of the individual dataset and across disparate datasets, data types and disciplines.
Innovation strategy at Danaher
Innovating at the intersection of AI and biomedicine
We combine massive global reach with deep rigor in how we design, collect, store and share the data that shape our innovations, enabling us to innovate intelligently and build smart tools that propel progress in biomedicine.
Solutions that make a difference
We work to create solutions that increase accuracy, add critical context and can be deployed in fit-for-purpose interfaces to answer scientific questions and make our world healthier.
Value where it matters most
Our companies work across the full biomedical ecosystem and touch every part of the patient journey – from drug discovery to diagnosis to delivery. This gives us unique visibility into key challenges and enables us to develop and deploy AI-informed tools expressly designed to match.
Partnering to solve problems together
Technology is only as good as the people who use it. We partner with the best of the best – leading experts from tech, biotech, pharma and academia to ensure we are solving the most important problems in the most useful ways.
Our events
Time
9:44 am America/New_York
Innovation in the news
Meet Danaher’s Chief Data and AI Officer
We spoke with Martin Stumpe, PhD, Danaher’s newly appointed Chief Data and AI Officer, about the future of AI in healthcare and life sciences.
The future of pathology is digital
Rob Monroe, Vice President and Chief Scientific Officer of Oncology, Danaher Diagnostics Platform, illuminates how cutting-edge technology and AI-driven tools are transforming the art and science of disease diagnosis.
Danaher launches Beacon research collaboration with Stanford University aiming to build next generation of smart microscopes for cancer drug screening
Combining spatial biology with artificial intelligence, the research team at the Danaher Beacon for Spatialomics aims to help de-risk cancer drug development.